UK Life Sciences and Healthcare Newsletter - February 2021: Market News

Dechert LLP

[co-author: Alasdair Austin]*

Other recent notable industry transactions:

  • Thermo Fisher Scientific Inc. completed the acquisition of Henogen SA, Novasep's viral vector manufacturing business in Belgium for approximately €725 million in cash.
  • Haemonetics Corporation, a global medical technology company, announced its agreement to acquire Cardiva Medical, Inc., a manufacturer of vascular closure systems, for an upfront cash payment of US$475 million at with additional contingent consideration based on sales growth.
  • Boston Scientific entered into an agreement to acquire Preventice Solutions, Inc., company which offering mobile cardiac health solutions and services, for upfront cash payment of US$925 million, and up to US$300 million in a potential milestone payment. Boston Scientific was already an investor in Preventice.
  • Sanofi and Novartis have agreed to support the manufacturing and supply of BioNTech's COVID-19 vaccine (co-developed with Pfizer).
  • A new partnership between the UK government and CureVac (a vaccine manufacturer) has been agreed, in order to quickly develop new vaccines in response to new COVID-19 variants, if they are needed.

*Trainee Solicitor

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP
Contact
more
less

Dechert LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.